Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × capivasertib × 90 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9 Triple Negative Breast Neoplasms 3 Disease Progression 2 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Moderate Hepatic Impairment 1 Melanoma 1 Lymphoma 1 Leukemia 1 Healthy Participants 1

Interventions

Magnetic Resonance Spectroscopy 45 Specimen Handling 44 enzalutamide 41 Prednisone 33 apalutamide 30 Androgen Antagonists 30 Abiraterone Acetate 29 Leuprolide 24 darolutamide 21 Radiotherapy 21 Radiosurgery 21 Docetaxel 19 abiraterone 18 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 16 relugolix 15 Biopsy 15 Radiation 14 Pluvicto 14 cabazitaxel 13 X-Rays 13 Goserelin 13 prednylidene 11 luprolide acetate gel depot 11 deltacortene 11 bicalutamide 11 gallium 68 PSMA-11 10 Triptorelin Pamoate 10 Gonadotropin-Releasing Hormone 10 Glutamate Carboxypeptidase II 10 Carboplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04493853 2026-01-20

CAPItello-281

AstraZeneca

Phase 3 Active not recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡